Despite Profit Trim, J&J Wins Over Wall Street And Retail Investors: What’s Going On?

JNJ beats Q2 estimates. Retail on Stocktwits stays bullish on hopes of breaching $160 despite Stelara woes and litigation.
Profile Image
Ramakrishnan M·Stocktwits
Updated Jul 02, 2025   |   8:31 PM EDT
Share
·
Add us onAdd us on Google

Johnson & Johnson (JNJ) 's quarterly results on Wednesday kept both Wall Street and the retail segment happy despite some minor worries. 

While its pre-market share price dipped, presumably as the company trimmed its full-year profit outlook, things turned positive in opening trading as the stock rose 3.70% to $156.63.

The Stocktwits sentiment score was bullish (70/100), and message volume hit its highest this year (95/100). So, what's behind the surge?

JNJ Sentiment and message meter Jul 17
JNJ Sentiment and message meter Jul 17

On the surface, things look rosy. J&J beat analyst estimates for both second-quarter profit and revenue. Sales of powerhouse drugs like Darzalex (cancer treatment) and Stelara (psoriasis) exceeded expectations, per Reuters, pushing overall revenue to $22.40 billion (above the $22.30 billion consensus). 

Adjusted earnings per share also landed at $2.82, surpassing the anticipated $2.71.

However, J&J's revised full-year forecast revealed that the company trimmed its profit projections to account for recent acquisitions, including the $13 billion purchase of cardiac device maker Shockwave. 

The Stocktwits community was mostly bullish, as many now lie in wait for JNJ to potentially breach the $160 mark, seemingly unfazed by the lowered outlook. 

Stocktwits users' posts on JNJ stream premarket Jul 17
Stocktwits users' posts on JNJ stream premarket Jul 17

This optimism might stem from J&J's impressive track record – the company has beaten earnings estimates for the past four quarters.

There are underlying concerns that could dampen the retail enthusiasm. JNJ's share price is already down 5.60% year-to-date. Investors are worried about two key issues:

1. Stelara's future: This blockbuster drug faces a future with lower-priced competition in both the U.S. and Europe, potentially impacting its sales.

2. Ongoing litigation: JNJ continues to battle legal challenges from people claiming its talc-based baby powder caused cancer.

But for now, both retail traders and the overall market are cheering JNJ’s upbeat results, and this momentum might bring some much-needed respite to the battered stock.

Photo courtesy: Open Grid Scheduler on Flickr
 

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy